Biotechnology US biotech firm Dendreon (Nasdaq: DNDN) pleased investors last week when it reported that revenue of its breakthrough prostate cancer treatment Provenge (sipuleucel-T) are stronger than expected, pushing the firm's shares more than 50% higher to $11.06 in morning trading on January 5, but still leaving the stock down nearly 75% in past six months as sales of the product struggled, partly due to its high treatment cost - about $93,000 per round of therapy - and uncertainties about reimbursement (The Pharma Letters passim). 8 January 2012